Clinical trial of autologous adiose tissue derived stromal cell therapy for ischemic heart failure - ADRC-IHF

Regarding the primary endpoint's safety, no adverse events were observed during the perioperative period and 6 months in all 3 patients. As secondary endpoints, the changes in cardiopulmonary function were evaluated. In one patient (case 2), maximal oxygen uptake increased, and in two patients (cases 2 and 3), exercise tolerance (6 minutes walking distance) improved. On the other hand, there was one patient (case 1) in which the cardiopulmonary function did not change.